<DOC>
	<DOCNO>NCT02734849</DOCNO>
	<brief_summary>This phase 2 study evaluate multiple dose AK001 across 2 active dos . Pharmacodynamic activity also evaluate .</brief_summary>
	<brief_title>Study Evaluate Multiple Doses Patients With Nasal Polyposis</brief_title>
	<detailed_description>AK001 monoclonal antibody may useful treatment patient moderate severe nasal polyposis</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Nasal Polyps</mesh_term>
	<criteria>TPS ≥5 nostrils presence endoscopy nasal polyp grade ≥2 nostril accord polyp grade scale History sinusitis symptom SNOT22 ≥30 No clinically significant Screening 12lead ECG , vital sign , hematology , chemistry , urinalysis finding Use systemic corticosteroid within 6 week screen Chronic use antibiotic therapy within 3 month prior Screening Nasal surgery ( include polypectomy ) within 6 month prior Screening Use investigational drug participation another clinical trial within 30 day prior Screening 5 half‑lives , whichever long</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>